Small molecule inhibitors of RGS proteins
The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
1. A composition comprising a compound having the structure:
wherein R 1 is selected from the group consisting of
C2-C4 alkyl-OR 3 , C1-C3 alkyl-heteroaryl-R 3 , C4-C10 cycloalkyl wherein one or more CH 2 is replaced by O, and C2-C6 alkynyl, optionally substituted; R2 is a C2-C4 alkyl; R 3 is selected from the group consisting of C1-C6 alkyl, C0-C4 alkyl-aryl, C0-C4 alkyl-heteroaryl, and C2-C4 alkyl-OR 4 ; and R 4 is C1-C4 alkyl.
2. The composition of claim 1 , wherein R 1 is selected from the group consisting of C2-C4 alkyl-OR 3 ; C1-C3 alkyl-heteroaryl-R 3 ; C4-C10 cycloalkyl, wherein at least one CH 2 is replaced by O; and C2-C6 alkynyl; R2 is a C2-C4 alkyl R 3 is selected from the group consisting of C1-C6 alkyl, C0-C4 alkyl-aryl, C0-C4 alkyl-heteroaryl, and C2-C4 alkyl-OR 4 ; and R 4 is C1-C4 alkyl.
3. The composition of claim 1 , wherein R 1 is C2-C3 alkyl-O—C1-C4 alkyl and R2 is a C2-C4 alkyl.
4. The composition of claim 1 , wherein said heteroaryl is 1,2,3-triazole.
5. The composition of claim 1 , wherein R3 is selected from the group consisting of CH 3 , CH 2 CH 3 , and CH 2 Ph.
6. The composition of claim 1 , wherein said compound is selected from the group consisting of,
7. The composition of claim 1 , wherein said composition is a pharmaceutical composition.
8. The composition of claim 7 , wherein said composition further comprises a pharmaceutically acceptable carrier.
9. A method of inhibiting a regulator of G-protein Signaling (RGS) domain protein, comprising contacting said protein with a compound having the structure:
wherein R 1 is selected from the group consisting of
C2-C4 alkyl-OR 3 , C1-C3 alkyl-heteroaryl-R 3 , C4-C10 cycloalkyl wherein one or more CH 2 is replaced by O, and C2-C6 alkynyl, optionally substituted, R2 is a C2-C4 alkyl; R 3 is selected from the group consisting of C1-C6 alkyl, C0-C4 alkyl-aryl, C0-C4 alkyl-heteroaryl, and C2-C4 alkyl-OR 4 ; and R 4 is C1-C4 alkyl.
10. The method of claim 9 , wherein R 1 is selected from the group consisting of C2-C4 alkyl-OR 3 ; C1-C3 alkyl-heteroaryl-R 3 ; C4-C10 cycloalkyl, wherein at least one CH 2 is replaced by O; and C2-C6 alkynyl; R2 is a C2-C4 alkyl; R 3 is selected from the group consisting of C1-C6 alkyl, C0-C4 alkyl-aryl, C0-C4 alkyl-heteroaryl, and C2-C4 alkyl-OR 4 ; and R 4 is C1-C4 alkyl.
11. The method of claim 9 , wherein R1 is C2-C3 alkyl-O—C1-C4 alkyl and R2 is a C2-C4 alkyl.
12. The method of claim 9 , wherein said heteroaryl is 1,2,3-triazole.
13. The method of claim 9 , wherein R 3 is selected from the group consisting of CH 3 , CH 2 CH 3 , and CH 2 Ph.
14. The method of claim 9 , wherein said compound is selected from the group consisting of
15. The method of claim 9 , wherein said protein is in a cell.
16. The method of claim 15 , wherein said cell is in an animal.